Immunotherapy and long‑term chemoprophylaxis in prevention of recurrent urinary infections in women

Czech version

Authors: S. Krčméry ¹; J. Hromec ²; Z. Gábrišová ¹; R. Tahotný ¹
Authors‘ workplace: II. klinika geriatrie Lekárskej fakulty UK a FNsP Milosrdní bratia, spol. s r. o., Bratislava, Slovenská republika, prednosta doc. MU Dr. Silvester Krčméry, CSc. ¹; Interná klinika FZaSP a FNsP Trnava, Slovenská republika, prednosta prof. MU Dr. Juraj Hromec, CSc. ²
Published in: Vnitř Lék 2010; 56(9): 955-960
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Overview

In clinical practice, management of urinary infections is a frequent task. Long‑term prophylactic administration of small‑dose chemotherapy had been shown to prevent recurrent urinary infections. Recently, an interest increases in applying immunotherapy in this indication. The authors compare immunomodulators Urovaxom and Luivac as part of a combined immunotherapy and chemoprophylaxis regimens with small doses of fluorochinolones over 12 months in women with recurrent urinary infections. This treatment statistically significantly decreases occurrence of relapses and has been relatively well‑tolerated. Unlike previous studies, we managed to isolate resistant strains producing the so‑ called extended‑ spectrum β‑ lactamases (ESBL) and this may provide a signal for revision of some therapeutic approaches. In line with international recommendations, we prefer immunotherapy as comparably effective but safer treatment modality than the long‑term chemoprophylaxis with fluorochinolones.

Key words:
urinary infections – combined chemoprophylaxis and immunotherapy – relapse prevention

Sources

1. Ronald AR, Pattudo AL. The natural history of urinary infections in adults. Med Clin North Am 1991; 75: 299– 312.

2. Foxman B, Barlow R, D’Arcy H et al. Urinary tract infection: self‑ reported incidence and associated costs. Ann Epidemiol 2000; 10: 509– 515.

3. Bauer HW, Alloussi S, Egger G et al. A long‑term, multicenter, double‑blind study of an Escherichia coli extract (OM‑ 89) in female patients with recurrent urinary tract infections. Eur Urol 2005; 47: 542– 548.

4. Pfau A, Sacks TG. Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women. J Urol 1994; 152: 136– 138.

5. Hooton TM. Recurrent urinary tract infections in women. Int J Antimicrob Agents 2001; 17: 259– 268.

6. Krčméry S, Demešová D, Dúbrava M et al. Chemoterapia uroinfekcií. Bratislava: Charis 2000.

7. Kahlmeter G. ECO SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO SENS Project. J Antimicrob Chemother 2003; 51: 69– 76.

8. Weidner W. Editorial Comment. Eur Urol 2005; 47: 548.

9. Frey C, Obolensky W, Wyss H. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int 1986; 41: 444– 446.

10. Tammen H. German Urinary Tract Infection Study Group. Immunobiotherapy with Uro‑Vaxom in recurrent urinary tract infection. Br J Urol 1990; 65: 6– 9.

11. Schulmann CC, Corbusier A, Michiels Het al. Oral immunotherapy of recurrent urinary tract infections: a double‑blind, placebo‑ controlled multicenter study. J Urol 1993; 150: 917– 921.

12. Magasi P, Pánovics J, Illés A et al. Uro‑Vaxom and the management of recurrent urinary tract infection in adults: a randomised, multicenter, double‑blind trial. Eur Urol 1994; 26: 137– 140.

13. Krieger JN. Urinary tract infections: what’s new? J Urol 2002; 168: 2351– 2358.

14. Valiquette L. Urinary tract infections in women. Can J Urol 2001; 8 (Suppl 1): 6– 12.

15. Aubel van A, Hofbauer C, Elsesser U et al. Immunoglobulins in serum and saliva of children with recurrent infections of the respiratory tract during treatment with an oral immunomodulator. In: Masihi KH (ed). Immunotherapy of infections. New York: Marcel Dekker 1994: 357– 359.

16. Grevers G, Palacios OA, Rodriguez B et al. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study. Adv Ther 2000; 17: 103– 116.

17. Kitzler P, Ferreira Branco AP, Willinger B et al. Immunomodulating treatment of recurrent respiratory tract infections. A multinational postapproval study with Luivac/ Paspat oral. J Pharmacol Therapy 2005; 5: 135– 141.

18. Rossi S, Tazza R. Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infections. A randomised, open, controlled clinikal trial. Arzneimittelforschung 2004; 54: 50– 56.

19. Ruah SB, van Aubel A, Abel S et al. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv Ther 2001; 18: 151– 162.

20. Debelic M, Eckenberger HP. Prevention of recurrent infections of the upper and lower airways. Multicenter, open study over three months. Fortschr Med 1992; 110: 565– 570.

21. Klička J, Pružinec P, Hromec J. Orálne imunoterapeutikum Luivac v liečbe recidivujúcich respiračných infektov. Klin Imunol Alergol 2000; 10: 34– 36.

22. Karlowsky JA, Jones ME, Thornsberry C et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1672– 1680.

23. Melekos MD, Asbach HW, Gerharz E et al. Long‑term post‑ intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997; 157: 865– 878.

24. Grabe M, Bjerklund‑ Johansen TE, Botto H et al. Guidelines on Urological Infections. Paris: European Association of Urology 2010.

25. Krčméry S, Hromec J. Dlhodobá chemoprofylaxia a imunoterapia v prevencii recidivujúcich uroinfekcií u žien. Via Practica 2006; 3: 190– 193.